Merck & Co.

PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights

Retrieved on: 
Giovedì, Maggio 9, 2024
PMV, Research, Pembrolizumab, Merck & Co., Patient, Merck, Pharmaceutical industry

“Dosing the first patient in the registrational, tumor-agnostic Phase 2 portion of the PYNNACLE trial was an important milestone for PMV.

Key Points: 
  • “Dosing the first patient in the registrational, tumor-agnostic Phase 2 portion of the PYNNACLE trial was an important milestone for PMV.
  • Net loss for the quarter ended March 31, 2024, was $15.3 million compared to $19.1 million for the quarter ended March 31, 2023.
  • Research and development (R&D) expenses were $13.2 million for the quarter ended March 31, 2024, compared to $15.1 million for the quarter ended March 31, 2023.
  • General and administrative (G&A) expenses were $5.0 million for the quarter ended March 31, 2024, compared to $6.4 million for the quarter ended March 31, 2023.

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Mercoledì, Maggio 8, 2024
MSD, Investment, Pancreatic cancer, Research, TCE, CRC, Trial of the century, Webcast, Drug discovery, EGFR, Bladder cancer, Cancer, CRS, Cytokine, Tumor microenvironment, ADC, Vomiting, Therapeutic index, Kidney, Bristol Myers Squibb, Therapy, Biotechnology, Spacecraft, SAN, Arthralgia, Safety, Pembrolizumab, RECIST, Arthritis, GLP, Melanoma, BMS, Toxicology, CD3, EDT, Itch, Merck & Co., PDT, Camptothecin, Patient, Rash, Head, Epithelial cell adhesion molecule, Amgen, Pharmaceutical industry

Initial data anticipated in 2025 -

Key Points: 
  • Initial data anticipated in 2025 -
    - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT -
    SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today reported first quarter 2024 financial results and provided a business update.
  • The Company expects to provide an additional Phase 1a dose escalation update by the end of 2024.
  • The cash balance as of March 31, 2024, does not include the $10.0 million of Astellas milestone achievements earned in the first quarter of 2024.
  • CytomX management will host a conference call and simultaneous webcast today at 5 p.m. EDT (2 p.m. PDT) to discuss the financial results and provide a business update.

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

Retrieved on: 
Martedì, Maggio 7, 2024
MSD, Cancer, Merck & Co., Patient, Renal cell carcinoma, Melanoma, Head, Clinical trial, Therapy, SAN, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the US and Canada) for CytomX’s first-in-human Phase 1 clinical trial assessing the clinical activity of CX-801, a dually-masked interferon-alpha2b cytokine in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab).

Key Points: 
  • “Interferon-alpha-2b is a potent cytokine with demonstrated clinical activity against multiple cancer types, but its use has been limited by systemic toxicities.
  • CX-801 is designed to overcome these limitations to unlock the full potential of interferon in activating the immune tumor microenvironment.
  • “CytomX is excited to be entering into this agreement with Merck to utilize Keytruda in combination with CX-801.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent

Retrieved on: 
Giovedì, Maggio 9, 2024
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, MSD, B21, Radiation, DFS, Paclitaxel, Food, Merck & Co., Immunotherapy, Eisai, Data monitoring committee, Rated R, PDUFA, ADC, Patient, Endometrial cancer, Cancer, MSI-H, Carboplatin, MRK, Pharmaceutical industry

The study’s other primary endpoint of overall survival (OS) was not formally tested since superiority was not reached for DFS.

Key Points: 
  • The study’s other primary endpoint of overall survival (OS) was not formally tested since superiority was not reached for DFS.
  • The safety profile of KEYTRUDA was consistent with that observed in previously reported studies; no new safety signals were identified.
  • Merck will work with investigators to share the results with the scientific community.
  • “We would like to thank all the patients, the investigators and our study collaborators for their participation in this trial.”
    In the U.S., KEYTRUDA has two approved indications in endometrial cancer.

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types

Retrieved on: 
Giovedì, Maggio 2, 2024
Oncology, Health, Other Health, General Health, Research, Science, Pharmaceutical, FDA, Cancer, Safety, CD4, Serum, Carcinoma in situ, MHC, Grand Bahama International Airport, Vaccine, BCG, SII, Merck & Co., CIS, Patient, Medicine, NMIBC, Standard of care, Neoplasm, GMP, Bladder cancer, Serum Institute of India, CD8, Escape Room

ImmunityBio, Inc. ( NASDAQ: IBRX ), has signed an exclusive global arrangement with the Serum Institute of India, the world’s largest manufacturer of vaccines by number of doses produced, to supply ImmunityBio with Bacillus Calmette-Guerin (BCG).

Key Points: 
  • ImmunityBio, Inc. ( NASDAQ: IBRX ), has signed an exclusive global arrangement with the Serum Institute of India, the world’s largest manufacturer of vaccines by number of doses produced, to supply ImmunityBio with Bacillus Calmette-Guerin (BCG).
  • Increasing the available supply of BCG is intended to address shortages for the combination therapy with ANKTIVA.
  • “The collaboration between Serum Institute of India and ImmunityBio will undoubtedly transform the way we approach cancer treatment.
  • We look forward to exploring ANKTIVA in combination with BCG in non-muscle invasive bladder cancer (NMIBC) and across other tumor types.

BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS

Retrieved on: 
Martedì, Aprile 30, 2024
Science, Executive, Universidad, Bristol Myers Squibb, Research, Bio-Techne, Merck & Co., Novartis, Therapy, SVP, Merck

MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024.

Key Points: 
  • MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024.
  • Dr. Klimovsky will serve as a member of the Science and Technology Committee.
  • Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent.
  • "We are pleased to welcome Dr. Klimovsky to our board," said Bob Baumgartner, Chairman of the Board of Bio-Techne.

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

Retrieved on: 
Mercoledì, Aprile 24, 2024
Cure, Safety, Tumor microenvironment, Intelligence, PDAC, ASCO, Merck & Co., Society, Poster, Annual general meeting, Therapy, Merck, Pharmaceutical industry

NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that a late-breaking abstract with preliminary findings from the Phase 2 investigator-sponsored trial of BXCL701 in combination with KEYTRUDA® (pembrolizumab) in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) has been selected for presentation in a poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place from May 31 to June 4, 2024 in Chicago, IL.

Key Points: 
  • The meeting will take place from May 31 to June 4, 2024 in Chicago, IL.
  • On February 6, 2024, BioXcel Therapeutics announced the completion of patient enrollment in the safety lead-in portion of the trial.
  • Through its OnkosXcel Therapeutics immuno-oncology subsidiary, BioXcel Therapeutics is collaborating with Dr. Louis M. Weiner, director of the Lombardi Comprehensive Cancer Center, and Dr. Benjamin Weinberg, principal investigator of the study.
  • BioXcel Therapeutics and Merck & Co. are providing BXCL701 and KEYTRUDA for the trial, respectively.

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Retrieved on: 
Mercoledì, Aprile 24, 2024
CPS, Cancer, DCR, HNSCC, Data collection, QOL, Neck, Pembrolizumab, Merck & Co., CQD, ASX, Fast track (FDA), PD-L1, Data, Autoimmune disease, Incidence, Patient, Head, Death, Quality of life, Merck, Neoplasm, IMM, Medical imaging

SYDNEY, AUSTRALIA, April 24, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces preliminary topline results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alpha (efti) in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma patients (1L HNSCC) with negative PD-L1 expression.

Key Points: 
  • Head and neck squamous cell carcinomas are a heterogenous disease that represent a high unmet medical need regardless of PD-L1 expression.
  • A total of 33 patients with recurrent or metastatic HNSCC have been enrolled into Cohort B.
  • The final number of evaluable patients in Cohort B is expected to be higher and additional data, including complete response rate, will be released together with Cohort A data.
  • Patients in Cohort A are stratified by CPS >1, CPS 1-19, and CPS >20, and the clinical results for these three CPS groups will be evaluated.

Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian

Retrieved on: 
Martedì, Aprile 23, 2024
Nature Immunology, School, University, Cancer, Biogen, COVID, SAB, Remdesivir, Medical school, Merck & Co., Los Angeles School, Eli Lilly, Amgen, Developmental Biology (journal), Inflammation, STAT3, Molecular biology, Yale University, Research, Lupus, STAT6, Growth, SH2, JAMA, Eli Lilly and Company, UCSF, Patient, Doctor of Pharmacy, Rheumatoid arthritis, Psoriasis, Vasculitis, Morphic, Lilly, Multiple sclerosis, Drug discovery, SAN, Division, Investigational New Drug, Science and nature, Pharmaceutical industry

“We are thrilled to welcome Ajay and Adrian to Recludix,” said Nancy Whiting, PharmD, CEO of Recludix. “Ajay joins us from Eli Lilly with over two decades of executive leadership experience spanning all stages of drug discovery and development. He has extensive expertise in immunology and has led the advancement and strategic oversight of deep pipelines with more than ten product candidates reaching the clinic during his Lilly tenure. At Recludix, we have a robust pipeline of validated targets, starting with our two lead programs -- oral and reversible inhibitors of STAT3 and STAT6. Additionally, our proprietary drug discovery platform has enabled us to drug many other exciting previously undruggable SH2 domain targets. Ajay’s deep experience leading a broad discovery and development immunology portfolio – both internally and through strategic partnerships -- is ideally suited to capitalize on the many opportunities at Recludix.”

Key Points: 
  • “We are thrilled to welcome Ajay and Adrian to Recludix,” said Nancy Whiting, PharmD, CEO of Recludix.
  • “Ajay joins us from Eli Lilly with over two decades of executive leadership experience spanning all stages of drug discovery and development.
  • At Recludix, we have a robust pipeline of validated targets, starting with our two lead programs -- oral and reversible inhibitors of STAT3 and STAT6.
  • Additionally, our proprietary drug discovery platform has enabled us to drug many other exciting previously undruggable SH2 domain targets.

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

Retrieved on: 
Martedì, Aprile 16, 2024
University, Cancer, Organic chemistry, University of Pennsylvania, AI, Merck & Co., Johnson & Johnson, Data science, Najat, Doctor of Philosophy, Research, Artificial intelligence, Entrepreneurship, Science, Patient, Chemistry, Biology, Ethics, Colgate University, Drug discovery, Committee, Economics, Computational chemistry, Pharmaceutical industry

SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer.

Key Points: 
  • SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer.
  • Dr. Khan will lead Recursion’s research and development, and build its emerging commercial capabilities.
  • “Najat brings a unique blend of leadership in biological, chemical, and medical sciences, data science, and business,” said Chris Gibson, Co-Founder and CEO of Recursion.
  • Najat is the founder and co-chair of the Data Science in Industry Roundtable (DISRUPT) – a cross industry forum dedicated to driving impact through Data Science.